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Is recurrent vaginal melanoma a lethal disease?Melanoma is a highly aggressive and invasive disease, and
occurs most commonly among the White populations. Since
this disease is rare among the Asian populations, it is not so
familiar to most physicians in Asian countries. In the 2011
issue of the JCMA, Lin and colleagues reported a case of
melanoma1 that is worthy of our attention. The reasons are
shown below. First, this Taiwanese woman was diagnosed as
having primary melanoma of the vagina.1
Second, although this woman initially underwent very
aggressive and extensive treatment, including radical vulvec-
tomy and total vaginectomy, and reconstruction with a rotation
flap, followed by immediate immunotherapy, the patient had
a relatively short disease-free interval (7 months). Then, the
nightmares began with recurrence again and again in both
local and distant areas.1 This is consistent with the recent
report from Frumovitz et al, which showed that malignant
vaginal melanoma, even when localized at presentation, has
a very poor prognosis.2 Using the “never give up” strategy,
aggressive and active multi-modality combination therapies
were given to this patient again and again, and she remained
alive for more than 30 months.
Ofmost importance, this patient underwent repeated complete
resections of the tumors in the local area, suggesting that the
repeat surgery should be considered as an adjuvant therapy for
local recurrent tumor. In fact, a recent report also favored the role
of surgery in the management of malignant vaginal melanoma,
because the patients who underwent surgery were found to
survive significantly longer than those who did not ( p ¼ 0.01).2
Furthermore, this case of Dr. Lin1 in this issue raises
a question about the possibility or necessity of long-term
treatment for cancer patients if the cancer is theoretically
never cured. To respond to this question, the concept of
metronomic therapy should be introduced. Metronomic
chemotherapy is the process of administration of cytotoxic
drugs on a more continuous basisdwith a much shorter break
period or none at all, and with generally low doses of various
cytotoxic drugs or combinations with other neweretargeted
therapies, for example, antiangiogenic agents.3 However, the
candidate medications that have been used recently and
frequently for metronomic therapy are not so patient-friendly.
Many of them should be given by parenterally, not orally. For
example, a Phase 2 pilot trial of combined intravenous metro-
nomic paclitaxel and oral celecoxib showed an impressive result1726-4901/$ - see front matter Copyright  2011 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.06.003for patients withmetastatic melanoma,4 but surely no onewould
like to be treated with a continuous intravenous infusion of
paclitaxel 10 mg/m2 for 96 hours weekly.
Cancer treatment is still a big challenge. Although “cure” is
a goal, “stability” might be an alternative if cure is impossible.
As a doctor, the concept of “a more friendly treatment, a more
acceptable outcome” should always be reminded.
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